
Norovirus Infection - Pipeline Insight, 2024
Description
Norovirus Infection - Pipeline Insight, 2024
DelveInsight’s, “Norovirus Infection - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Norovirus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Norovirus Infection: Overview
Norovirus Infection typically causes acute gastroenteritis. It is also a common cause of food poisoning and is usually related to consumption of undercooked shellfish. People can get Norovirus Infection from having direct contact with an infected person, consuming contaminated food or water, or by touching contaminated surfaces. Norovirus can also cause outbreaks of acute gastroenteritis in settings where people are staying close together such as schools, elderly homes, hotels, play facilities and cruise ships. The disease affects people of all age groups and tends to be more common during winter. The virus is previously known as ‘Norwalk-like viruses’.
The signs and symptoms of norovirus infection may start suddenly and include nausea, vomiting, stomach pain or cramps, watery or loose diarrhea, feeling ill, low-grade fever and muscle pain. Signs and symptoms usually begin 12 to 48 hours after the first exposure to a norovirus and last 1 to 3 days. Some people with norovirus infection may show no signs or symptoms. However, they're still contagious and can spread the virus to others. Noroviruses are highly contagious. That means the norovirus infection can easily spread to others. The infection can be caused by eating contaminated food, drinking contaminated water and by touching hand to mouth after the hand has been in contact with a contaminated surface or object and being in close contact with a person who has norovirus infection. Noroviruses are difficult to kill because they can withstand hot and cold temperatures and many disinfectants.
Norovirus infection is usually diagnosed based on the symptoms, but noroviruses can be identified from a stool sample. If the patient have a weakened immune system or have other medical conditions, the health care provider might recommend a stool test to confirm the presence of norovirus. There's no specific treatment for norovirus infection. Recovery generally depends on the health of immune system. In most people, the illness usually resolves within a few days. It's important to replace lost fluids. Oral rehydration solutions may be used. If the patient is not able to drink enough fluids to prevent dehydration, might need to receive fluids through a vein (intravenous).
There are many types of noroviruses. Anyone can get norovirus infection more than once. To prevent norovirus infection: wash your hands thoroughly with soap and water for at least 20 seconds, avoid contaminated food and water, wash fruits and vegetables before eating, Cook seafood thoroughly and avoid contact with others as much as possible.
""Norovirus Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Norovirus Infection pipeline landscape is provided which includes the disease overview and Norovirus Infection treatment guidelines. The assessment part of the report embraces, in depth Norovirus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Norovirus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Norovirus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Norovirus Infection.
This segment of the Norovirus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Norovirus Infection Emerging Drugs
- VXA-G1.1-NN: Vaxart
- CDI 988: Cocrystal Pharma Inc
Further product details are provided in the report……..
Norovirus Infection: Therapeutic Assessment
This segment of the report provides insights about the different Norovirus Infection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Norovirus Infection
- There are approx. 8+ key companies which are developing the therapies for Norovirus Infection. The companies which have their Norovirus Infection drug candidates in the most advanced stage, i.e. phase III include, Vaxart.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Norovirus Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Norovirus Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Norovirus Infection drugs.
Norovirus Infection Report Insights
- Norovirus Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Norovirus Infection drugs?
- How many Norovirus Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Norovirus Infection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Norovirus Infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Norovirus Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vaxart
- Cocrystal Pharma Inc
- Prosit Sole Biotechnology
- HilleVax
- iosBio
- OstriGen
- VXA-G1.1-NN
- CDI 988
- PSP 001
- HIL 214
- Norovirus vaccine
- Research programme: antibodies
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Norovirus Infection : Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Norovirus Infection – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- VXA-G1.1-NN: Vaxart
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CDI 988: Cocrystal Pharma Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Norovirus Infection Key Companies
- Norovirus Infection Key Products
- Norovirus Infection - Unmet Needs
- Norovirus Infection - Market Drivers and Barriers
- Norovirus Infection - Future Perspectives and Conclusion
- Norovirus Infection Analyst Views
- Norovirus Infection Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.